Sibrotuzumab
Monoclonal antibody / From Wikipedia, the free encyclopedia
Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | FAP |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
![]() ![]() |
Close
In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]